

ANNEX

**CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES**

Medicinal product no longer authorised

CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES

The Member States shall ensure that the Marketing Authorisation Holder (MAH) provides physicians who are expected to prescribe/use Repso with a physician educational pack containing the following:

- The Summary of Product Characteristics
- Physician Leaflet

The Physician Leaflet should contain the following key messages:

- That there is a risk of severe liver injury and so regular measurement of ALT (SGPT) levels to monitor liver function is important. The information provided in the Physician Leaflet should provide information on dose reduction, discontinuation and wash out procedures in the event of raised ALT.
- The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate)
- That there is a risk of teratogenicity and so pregnancy must be avoided until leflunomide plasma levels are at an appropriate level. Physicians and patients should be made aware that there is an ad hoc advisory service available to provide information on leflunomide plasma level laboratory testing
- The risk of infections, including opportunistic infections, and the contraindication for use in immuno-compromised patients.
- The need to counsel patients on important risks associated with leflunomide therapy and appropriate precautions when using the medicine.

Medicinal product no longer authorised